1. Home
  2. STOK vs IGIC Comparison

STOK vs IGIC Comparison

Compare STOK & IGIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STOK
  • IGIC
  • Stock Information
  • Founded
  • STOK 2014
  • IGIC 2001
  • Country
  • STOK United States
  • IGIC Jordan
  • Employees
  • STOK N/A
  • IGIC N/A
  • Industry
  • STOK Biotechnology: Pharmaceutical Preparations
  • IGIC Property-Casualty Insurers
  • Sector
  • STOK Health Care
  • IGIC Finance
  • Exchange
  • STOK Nasdaq
  • IGIC Nasdaq
  • Market Cap
  • STOK 997.9M
  • IGIC 1.0B
  • IPO Year
  • STOK 2019
  • IGIC N/A
  • Fundamental
  • Price
  • STOK $19.76
  • IGIC $24.14
  • Analyst Decision
  • STOK Strong Buy
  • IGIC Buy
  • Analyst Count
  • STOK 6
  • IGIC 2
  • Target Price
  • STOK $26.60
  • IGIC $31.50
  • AVG Volume (30 Days)
  • STOK 920.7K
  • IGIC 97.3K
  • Earning Date
  • STOK 08-12-2025
  • IGIC 08-05-2025
  • Dividend Yield
  • STOK N/A
  • IGIC 0.41%
  • EPS Growth
  • STOK N/A
  • IGIC 11.00
  • EPS
  • STOK 0.91
  • IGIC 2.79
  • Revenue
  • STOK $199,893,000.00
  • IGIC $535,109,000.00
  • Revenue This Year
  • STOK $415.58
  • IGIC $6.05
  • Revenue Next Year
  • STOK N/A
  • IGIC $7.01
  • P/E Ratio
  • STOK $21.55
  • IGIC $8.59
  • Revenue Growth
  • STOK 1218.82
  • IGIC 9.99
  • 52 Week Low
  • STOK $5.35
  • IGIC $17.06
  • 52 Week High
  • STOK $20.00
  • IGIC $27.76
  • Technical
  • Relative Strength Index (RSI)
  • STOK 78.62
  • IGIC 49.95
  • Support Level
  • STOK $19.07
  • IGIC $24.15
  • Resistance Level
  • STOK $19.91
  • IGIC $24.74
  • Average True Range (ATR)
  • STOK 1.26
  • IGIC 0.54
  • MACD
  • STOK 0.14
  • IGIC -0.04
  • Stochastic Oscillator
  • STOK 96.55
  • IGIC 20.58

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

About IGIC International General Insurance Holdings Ltd.

International General Insurance Holdings Ltd is an international specialist commercial insurer and a reinsurer, underwriting a diverse portfolio of specialty lines. The company operates in a portfolio of Energy, Property, Construction, Engineering, Ports and terminals, Financial Institutions, General Aviation, Professional Indemnity, Casualty, Directors and Officers, Political Violence, Forestry, and Treaty Reinsurance. Its operating segment includes Specialty Longtail; Specialty Short tail and Reinsurance.

Share on Social Networks: